Alex Denner, Sarissa Capital Management founder, discusses the opportunity in ARIAD Pharmaceuticals.» Read More
Corey Davis, Canaccord Genuity, discusses big deals in pharmaceutical including Teva's bid for Mylan.
CNBC's Meg Tirrell reports on Abbott Laboratories' earnings and deals associated with this company.
David Seaburg, head of sales trading at Cowen and Company, explains why there's more M&A to come in the biotech and pharmaceutical sector.
Amgen's product sales rose 12 percent as the company easily beat Wall Street's first-quarter earnings and revenue estimates.
Teva is offering $40 billion to buy Mylan. Barbara Ryan, Clemont Partners, and CNBC's Meg Tirrell, provide perspective on the potential consolidation.
A study of 95,000 kids found absolutely no link between the measles vaccine and autism, even in children with autistic siblings.
Color Genomics plans to charge only $249 for an analysis of cancer-risk genes. New York Times reports.
Changes in the prescription drug market may have curbed prescription opioid abuse but may have also fueled a rise in heroin use.
Drugmaker Teva is considering making a bid for Mylan, but has not yet made a decision on an offer, Dow Jones reported.
CNBC's Meg Tirrell provides insight to a report on Teva Pharmaceutical Industries Ltd. exploring a takeover offer from Mylan.
Biotech investors are going to be busy with new data on Alzheimer's drugs, cancer and genetic disorders on the way. Here's what analysts are watching.
For Pfizer and Merck, two big names that have ridden the merger wave, buying up more business is a possibility, their CEOs said.
Discussing the growth in the biotech industry, and current trading action, with Nasdaq OMX CEO Robert Greifeld.
After an abrupt departure, Former Teva CEO Jeremy Levin is now leading a start-up focused on rare neurological disorders.
Is it the golden age for cancer research Stephen Isaacs, Aduro Biotech CEO, discusses some of the advances in medicine of late.
Australia is making it harder for parents to file personal objections against vaccination.
Johnson & Johnson reports quarterly earnings that beat expectations despite a 7.2 percent drag on the strong dollar.
It can cost $75,000 to $250,000, and the names keep getting stranger as companies balance regulator concerns with the desire to market the product.
CNBC "Fast Money" traders discussed how to trade big names in the surging but uncertain biotechnology sector.
The "Halftime Report" traders give their trades for the second half.
Get the best of CNBC in your inbox